Rhumbline Advisers Ocugen, Inc. Call Options Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding OCGN
# of Institutions
88Shares Held
32.8MCall Options Held
518KPut Options Held
345K-
Vanguard Group Inc Valley Forge, PA12MShares$21 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.8MShares$6.65 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$5.62 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$4.56 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.93MShares$3.37 Million0.0% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $379M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...